Celecoxib: A COX-2 inhibitor for the treatment of osteoarthritis and rheumatoid arthritis

Formulary

Volumn 34, Issue 5, 1999, Pages 405-417

  Boyce, Eric G ^a   Breen, Gail A ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR;

CLINICAL TRIAL; DRUG ABSORPTION; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; OSTEOARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0032973985     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Data on file. G.D. Searle & Co, Skokie, IL.
2. Meade EZ, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isoenzymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993;268:6610-14.
3. Jouzeau JY, Terlain B, Abid A, et al. Cyclo-oxygenase isoenzymes: How recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 1997;53:563-82.
4. Kurumbail RG, Stevens AM, Glerse JK, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. [Letter] Nature 1996;384:644-8.
5. Karim A, Tolbert D, Burton E, et al. SC-58635 (Celecoxib): A highly selective inhibitor of cyclooxygenase-2. Disposition kinetics in man and identification of its major CYP450 isozyme in its biotransformation. [Abstract 3469] Pharm Res 1997; 14(Suppl):S617.
6. Simon LS, Lanza FL, Pipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998;41:1591-602.
7. Hubbard RC, Geis GS, Woods E, et al. Efficacy, safety, and tolerability of celecoxib, a specific COX-2 inhibitor, in osteoarthritis (OA). [Abstract 982] Arthritis Rheum 1998;41(Suppl):S196.
8. Geis GS, Hubbard RC, Callison D, et al. Safety and efficacy of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis. [Abstract 1990] Arthritis Rheum 1998;41(Suppl):S364.
9. Geis GS, Stead H, Morant S, et al. Efficacy and safety of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis. [Abstract 1699] Arthritis Rheum 1998;41(Suppl):S316.
10. Hubbard RC, Mehlisch DR, Jasper DR, et al. SC-58615, a highly selective inhibitor of COX-2, is an effective analgesic in an acute post-surgical pain model. [Abstract] Invest Med 1996;44:2024.
11. Mehlisch DR, Hubbard RC, Isakson P, et al. Analgesic efficacy and plasma levels of a highly selective inhibitor of COX-2 (SC-58635;SC) in patients with post-surgical dental pain. [Abstract PIII-2] Clin Pharmacol Ther 1997;61:195.
12. Anon. Celecoxib for arthritis. Med Lett Drugs Ther 1999;41:11-12.
13. Mengle-Gaw L, Hubbard RC, Karim A, et al. A study of the platelet effects of SC-58635, a novel COX-2-selective inhibitor. [Abstract 374] Arthritis Rheum 1997;40 (Suppl):S93
14. Michalets EL. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18:84-112.
15. Karim A. The effect of SC-58635 (celecoxib), a highly selective inhibitor of cyclooxygenase-2 (COX-2), on the methotrexate pharmacokinetics in patients. [Abstract 3291] Pharm Res 1997;14(Suppl): S559.
16. Giovannucci E, Rimm EB, Stampfer MJ, et al. Aspirin use and the risk of colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121:241-6.
17. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997;48: 626-32.
18. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409-12. F